ReviewKidney international2010
Toward the development of podocyte-specific drugs.
Review in Kidney international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- A Constant Pressure-Driven Podocyte-on-Chip Model for Studying Hypertension-Induced Podocytopathy Pathomechanism and Drug Screening.Micromachines · 2025Article
- KIBRA upregulation increases susceptibility to podocyte injury and glomerular disease progression.JCI insight · 2023Article
- Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles.Frontiers in medicine · 2023Review
- Renal cell markers: lighthouses for managing renal diseases.American journal of physiology. Renal physiology · 2021Article
- Tangeretin Ameliorates Glucose-Induced Podocyte Injury through Blocking Epithelial to Mesenchymal Transition Caused by Oxidative Stress and Hypoxia.International journal of molecular sciences · 2020Article
- Establishment and functional characterization of the reversibly immortalized mouse glomerular podocytes (imPODs).Genes & diseases · 2018Article
- Silver nanoparticle modified surfaces induce differentiation of mouse kidney-derived stem cells.RSC advances · 2018Article
- High-content screening assay-based discovery of paullones as novel podocyte-protective agents.American journal of physiology. Renal physiology · 2018Article
- The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.The Journal of biological chemistry · 2017Article
- Podocyturia: Potential applications and current limitations.World journal of nephrology · 2017Review
- A High-Content Screening Technology for Quantitatively Studying Podocyte Dynamics.Advances in chronic kidney disease · 2017Review
- Podocyte-specific NF-κB inhibition ameliorates proteinuria in adriamycin-induced nephropathy in mice.Clinical and experimental nephrology · 2017Article
- Stop that podocyte!American journal of physiology. Renal physiology · 2017Article
- Podocyte NF-κB is dispensable for the pathogenesis of renal ischemia-reperfusion injury.Physiological reports · 2016Article
- Podocytes.F1000Research · 2016Review
- A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules.Journal of the American Society of Nephrology : JASN · 2015Article
- Extract of Rhizoma Polygonum cuspidatum reduces early renal podocyte injury in streptozotocin‑induced diabetic rats and its active compound emodin inhibits methylglyoxal‑mediated glycation of proteins.Molecular medicine reports · 2015Article
- Sirtuin1 Maintains Actin Cytoskeleton by Deacetylation of Cortactin in Injured Podocytes.Journal of the American Society of Nephrology : JASN · 2015Article
- Using zebrafish to study podocyte genesis during kidney development and regeneration.Genesis (New York, N.Y. : 2000) · 2014Review
- Slit diaphragm protein Neph1 and its signaling: a novel therapeutic target for protection of podocytes against glomerular injury.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Most kidney diseases that ultimately lead to end-stage renal failure originate within the glomerulus and are associated with proteinuria. Treatment options are unspecific and offer partial cures at best because available therapies do not primarily treat glomerular cells but rather act systemically and thus cause many side effects. Most glomerulopathies directly stem from injury to podocytes, cells that have a key role in the maintenance of the glomerular filter. Thus, these cells constitute an obvious and promising target for the development of novel kidney-protective drugs. During the last decade, enormous advances have been made in the understanding of podocyte structure and function. A number of pathways that are altered during glomerular diseases may be targeted by novel small- and large-molecule drugs as well as biologicals that have been identified in nephrology and other areas of drug development. Cultured podocytes provide a valuable model for high-throughput drug screening assays. Furthermore, podocytes have been shown to possess many features that make them particularly good target cells for renal protection. This mini-review discusses some of the most recent promising data related to potential drug therapy for proteinuria and kidney disease through direct podocyte targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.